felodipine has been researched along with Left Ventricular Hypertrophy in 18 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To compare the effects of active treatment compared with placebo on blood pressure, left ventricular hypertrophy, and quality of life among older stage 1 isolated systolic hypertensive patients, a randomized, double-blind, parallel-group, multicenter clinical trial comparing felodipine (2." | 9.09 | One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. ( Black, HR; DeQuattro, V; Elliott, WJ; Frishman, WH; Hwang, CT; Klibaner, MI; Liebson, PR; Montoro, R; Ruff, DA; Schleman, MM; Strom, JA; Weber, MA; Zhang, D, 2001) |
| "The aim of the study was to evaluate the efficacy over 1 year of of felodipine ER 5 and 10 mg once daily (od) in 12 Caucasian patients with left ventricular hypertrophy secondary to primary hypertension." | 9.08 | The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension. ( Boydak, B; Killiçcioglu, B; Nalbantgil, I; Onder, R; Terzioglu, E; Yilmaz, H, 1996) |
| "This perspective study was performed to demonstrate the prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril, in hypertensives of recent onset." | 9.08 | Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine. ( Cacciapuoti, F; Capasso, A; De Nicola, A; Gentile, S; Minicucci, F; Mirra, G, 1998) |
| "The SILVER (Study of Irbesartan in Left VEntricular hypertrophy Regression) trial is designed to test the hypothesis that the newly developed angiontensin-II receptor antagonist, irbesartan, will produce a greater reduction in left ventricular (LV) mass than felodipine ER, in a population of hypertensive patients defined by seated diastolic blood pressure (SeDBP) in the range 95-115 mmHg or seated systolic blood pressure (SeSBP) in the range 160-200 mm Hg." | 9.08 | Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression. ( Agabiti Rosei, E; Bregman, B; Brudi, P; Clairefond, P; Cohen, A; Dubourg, O; Gosse, P; Guéret, P; Williams, B, 1998) |
| " Drug dosage was determined in an initial stepped-care titration phase lasting six weeks." | 6.69 | Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension. ( De Rosa, ML; Della Guardia, D; Giordano, A; Lionetti, F; Maddaluno, G; Marsicani, N; Vigorito, C, 1999) |
| " To compare the effects of active treatment compared with placebo on blood pressure, left ventricular hypertrophy, and quality of life among older stage 1 isolated systolic hypertensive patients, a randomized, double-blind, parallel-group, multicenter clinical trial comparing felodipine (2." | 5.09 | One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. ( Black, HR; DeQuattro, V; Elliott, WJ; Frishman, WH; Hwang, CT; Klibaner, MI; Liebson, PR; Montoro, R; Ruff, DA; Schleman, MM; Strom, JA; Weber, MA; Zhang, D, 2001) |
| " Twenty five unmedicated patients with primary hypertension were randomised to initial therapy with either the calcium antagonist, felodipine, or a diuretic and doses titrated to achieve similar levels of blood pressure (BP)." | 5.08 | Assessment of effects of two anti-hypertensive regimens on overall cardiovascular risk. ( Jennings, GL; Korner, P; Laufer, E; Reid, C; Sudhir, K, 1995) |
| "The aim of the study was to evaluate the efficacy over 1 year of of felodipine ER 5 and 10 mg once daily (od) in 12 Caucasian patients with left ventricular hypertrophy secondary to primary hypertension." | 5.08 | The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension. ( Boydak, B; Killiçcioglu, B; Nalbantgil, I; Onder, R; Terzioglu, E; Yilmaz, H, 1996) |
| "In an open study, 16 patients with moderate essential hypertension were treated with 5 or 10 mg felodipine daily for 3 months." | 5.08 | Rest and effort hemodynamic responses during prolonged treatment with felodipine, 24-h blood pressure monitoring, and echocardiographic changes. ( Schwartz, J; Tobar, R; Zimlichman, R, 1997) |
| "This perspective study was performed to demonstrate the prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril, in hypertensives of recent onset." | 5.08 | Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine. ( Cacciapuoti, F; Capasso, A; De Nicola, A; Gentile, S; Minicucci, F; Mirra, G, 1998) |
| "The SILVER (Study of Irbesartan in Left VEntricular hypertrophy Regression) trial is designed to test the hypothesis that the newly developed angiontensin-II receptor antagonist, irbesartan, will produce a greater reduction in left ventricular (LV) mass than felodipine ER, in a population of hypertensive patients defined by seated diastolic blood pressure (SeDBP) in the range 95-115 mmHg or seated systolic blood pressure (SeSBP) in the range 160-200 mm Hg." | 5.08 | Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression. ( Agabiti Rosei, E; Bregman, B; Brudi, P; Clairefond, P; Cohen, A; Dubourg, O; Gosse, P; Guéret, P; Williams, B, 1998) |
| " To study further the interactions between dietary salt intake and antihypertensive drug treatment, we examined the effects of felodipine, a dihydropyridine derivative Ca2+ channel antagonist with natriuretic properties, on blood pressure and the development of left ventricular hypertrophy in the stroke-prone spontaneously hypertensive rats during different levels of sodium chloride in the diet." | 3.69 | Cardiovascular effects of felodipine are not antagonized by dietary salt. ( Karppanen, H; Laakso, J; Mervaala, EM, 1994) |
| "Enalapril was started at 10 mg/day, felodipine-ER at 5 mg/day and nifedipine-GITS at 30 mg/day, all once daily." | 2.70 | Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril. ( Joyner, CD; Leenen, FH; Myers, MG; Toal, CB, 2002) |
| " Drug dosage was determined in an initial stepped-care titration phase lasting six weeks." | 2.69 | Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension. ( De Rosa, ML; Della Guardia, D; Giordano, A; Lionetti, F; Maddaluno, G; Marsicani, N; Vigorito, C, 1999) |
| " At the end of the dosing interval, felodipine lowered office DBP (mm Hg) by -18 +/- 12/14 +/- 1 compared to -14 +/- 2/11 +/- 1 for nifedipine (P < or = ." | 2.68 | Differential effects of felodipine and nifedipine on 24-h blood pressure and left ventricular mass. ( Leenen, FH; Myers, MG; Tanner, J, 1995) |
| "Ramipril or felodipine treatments did not significantly affect the heart rate, either alone or in combination." | 1.30 | Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats. ( Karppanen, H; Laakso, J; Malmberg, L; Mervaala, EM; Teräväinen, TL; Vapaatalo, H, 1997) |
| "Arterial hypertension is a cardinal precursor of congestive heart failure, and diastolic dysfunction is the most frequent mechanism for it." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (77.78) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 1 |
| Zhang, X | 1 |
| Liu, L | 1 |
| Zanchetti, A | 1 |
| Leenen, FH | 2 |
| Myers, MG | 2 |
| Joyner, CD | 1 |
| Toal, CB | 1 |
| Tanner, J | 1 |
| Jennings, GL | 1 |
| Sudhir, K | 1 |
| Laufer, E | 1 |
| Korner, P | 1 |
| Reid, C | 1 |
| Mervaala, EM | 4 |
| Laakso, J | 4 |
| Karppanen, H | 4 |
| Nalbantgil, I | 1 |
| Onder, R | 1 |
| Killiçcioglu, B | 1 |
| Boydak, B | 1 |
| Terzioglu, E | 1 |
| Yilmaz, H | 1 |
| Mayet, J | 2 |
| Shahi, M | 2 |
| McGrath, K | 1 |
| Poulter, NR | 2 |
| Sever, PS | 2 |
| Foale, RA | 2 |
| Thom, SA | 2 |
| Teräväinen, TL | 3 |
| Malmberg, L | 3 |
| Vapaatalo, H | 3 |
| Pörsti, I | 1 |
| Zimlichman, R | 1 |
| Schwartz, J | 1 |
| Tobar, R | 1 |
| Cacciapuoti, F | 1 |
| Capasso, A | 1 |
| Mirra, G | 1 |
| De Nicola, A | 1 |
| Minicucci, F | 1 |
| Gentile, S | 1 |
| Cohen, A | 1 |
| Bregman, B | 1 |
| Agabiti Rosei, E | 1 |
| Williams, B | 1 |
| Dubourg, O | 1 |
| Clairefond, P | 1 |
| Brudi, P | 1 |
| Gosse, P | 1 |
| Guéret, P | 1 |
| Schwitter, J | 1 |
| De Marco, T | 1 |
| Globits, S | 1 |
| Sakuma, H | 1 |
| Klinski, C | 1 |
| Chatterjee, K | 1 |
| Parmley, WW | 1 |
| Higgins, CB | 1 |
| Anguita Sánchez, M | 1 |
| De Rosa, ML | 1 |
| Giordano, A | 1 |
| Della Guardia, D | 1 |
| Maddaluno, G | 1 |
| Lionetti, F | 1 |
| Marsicani, N | 1 |
| Vigorito, C | 1 |
| Ariff, B | 1 |
| Wasan, B | 1 |
| Chapman, N | 1 |
| Black, HR | 1 |
| Elliott, WJ | 1 |
| Weber, MA | 1 |
| Frishman, WH | 1 |
| Strom, JA | 1 |
| Liebson, PR | 1 |
| Hwang, CT | 1 |
| Ruff, DA | 1 |
| Montoro, R | 1 |
| DeQuattro, V | 1 |
| Zhang, D | 1 |
| Schleman, MM | 1 |
| Klibaner, MI | 1 |
12 trials available for felodipine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study.
Topics: Age Factors; Aged; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; C | 2010 |
Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril.
Topics: Antihypertensive Agents; Biomarkers; Blood Pressure; Data Interpretation, Statistical; Enalapril; Fe | 2002 |
Differential effects of felodipine and nifedipine on 24-h blood pressure and left ventricular mass.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 1995 |
Assessment of effects of two anti-hypertensive regimens on overall cardiovascular risk.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiovascular Diseases; Cholesterol; Diuretics; Drug Thera | 1995 |
The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Drug Administration Schedule; Felodipine; Female; H | 1996 |
Left ventricular hypertrophy and QT dispersion in hypertension.
Topics: Adult; Antihypertensive Agents; Echocardiography; Electrocardiography; Felodipine; Female; Hemodynam | 1996 |
Rest and effort hemodynamic responses during prolonged treatment with felodipine, 24-h blood pressure monitoring, and echocardiographic changes.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Echoca | 1997 |
Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Echocardiography; Felodip | 1998 |
Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
Topics: Adolescent; Adult; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Calcium Channel Bloc | 1998 |
Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: possible interaction with cyclosporine medication.
Topics: Analysis of Variance; Antihypertensive Agents; Cyclosporine; Diuretics; Drug Interactions; Felodipin | 1999 |
Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension.
Topics: Aged; Antihypertensive Agents; Chi-Square Distribution; Chlorthalidone; Drug Therapy, Combination; E | 1999 |
One-year study of felodipine or placebo for stage 1 isolated systolic hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Echocardiography; Felodipine; Fe | 2001 |
6 other studies available for felodipine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Cardiovascular effects of felodipine are not antagonized by dietary salt.
Topics: Animals; Blood Pressure; Cerebrovascular Disorders; Electrolytes; Felodipine; Heart Rate; Hemodynami | 1994 |
Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Drug Th | 1997 |
Cardiovascular and renal effects of the combination of felodipine and metoprolol during a high-salt and a moderate-salt diet in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Calcium Channel Blockers; Drug Therapy, Combin | 1997 |
Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pre | 1998 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy.
Topics: Adult; Antihypertensive Agents; Bendroflumethiazide; Blood Pressure; Cardiac Output; Echocardiograph | 2000 |